Friday Jul 31
HEALTHOther

Pharma Spends $7B, Ships Zero AI Drugs

31JUL
$7B0 DRUGS

Every major drugmaker is racing into AI drug discovery right now. Not one has an approved AI-designed medicine to show for it. The bill for that race already tops $7 billion.

Insilico Medicine alone signed pharma deals with Servier, Eli Lilly, SK Biopharma, and Takeda since January. Those four partnerships make up most of the total.

Insilico's rentosertib, the furthest along, only reached a Phase IIa efficacy signal. Nothing has cleared Phase III, the stage that actually decides approval. Early-stage success rates still match the industry's historic average.

The technology isn't failing, human trials are just slow and unforgiving. Investors are pricing this category like that problem is already solved.

full brief & sources

⚡ Why this matters

  • This is the clearest gap yet between AI drug discovery's funding and its actual output.
  • It's a warning for anyone valuing an AI biotech on pipeline size instead of trial results.
  • The bottleneck was never finding candidates, it's proving they work in humans.

🔍 What happened

  • Since January 2026, pharma companies committed over $7 billion to AI drug discovery deals with Insilico Medicine alone.
  • Partners include Servier in oncology, Eli Lilly in oral therapeutics, SK Biopharmaceuticals in neuroimmune disease, and Takeda.
  • Zero AI-discovered drugs are approved for patients anywhere, as of July 2026.
  • Insilico's rentosertib, the furthest-along AI-designed molecule, only reached a Phase IIa efficacy signal.
  • AI-derived molecules pass Phase I at 80-90% but drop to about 40% in Phase II, matching historical norms.
  • The average cost to turn any drug candidate into an approved drug is still about $2.6 billion.

💬 Smart takes

  • Elias Tharakan, cited in Clinical Trial Vanguard: the industry has committed more than $7 billion to Insilico deals alone since January, with zero approvals to show for it.
  • Clinical Trial Vanguard: "the industry is funding the wrong race."
  • Skeptic on the other side: a Phase IIa efficacy signal is real progress. Traditional drug discovery took decades to reach this point too.

🧭 Where this goes

  1. Likelyat least one Insilico or Isomorphic Labs candidate reaches a Phase III readout within 18 months.
  2. Likelypharma keeps signing AI deals regardless of trial outcomes, because the deals are cheap next to $2.6B per drug.
  3. Possibleone high-profile AI drug candidate fails Phase III publicly, denting the whole category's credibility.
  4. Wild Cardthe first AI-discovered drug wins approval before the end of 2027, resetting the narrative overnight.

🥄 The Spoon Take

AI drug discovery didn't fail, it hit the same wall every drug hits: slow, unforgiving human trials. The $7 billion bets AI shrinks that wall eventually. The zero approvals say it hasn't yet. Both are true, and that's the real story, not the hype or the debunking.

🤔 Pushback

Rentosertib's Phase IIa signal is a genuine result, and dismissing all AI drug discovery as hype ignores that one real data point.

·Clinical Trial Vanguard - $7B, zero approvals·IntuitionLabs - Lilly-Insilico deal